News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Vertex Pharmaceuticals Incorporated 1st-Quarter Loss Widens on Expenses
April 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, April 16 (Reuters) - Vertex Pharmaceuticals Inc. reported a wider first-quarter loss on Thursday due to high drug development costs and acquisition related and restructuring expenses.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Vertex Pharmaceuticals
MORE ON THIS TOPIC
Funding
Backed by NVIDIA and Anthropic, Basecamp bags $140M to advance AI-designed drugs
September 24, 2026
·
1 min read
·
Tristan Manalac
Deals
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
September 24, 2026
·
2 min read
·
Gabrielle Masson
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
September 24, 2026
·
1 min read
·
Tristan Manalac
Venture capital
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
September 23, 2026
·
1 min read
·
Annalee Armstrong
